Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy

Brain

Volumn 137, Issue 8, 2014, Pages 2155-2163

  Sung, Jia Ying ^a,b   Tani, Jowy ^a   Park, Susanna B ^c   Kiernan, Matthew C ^c,d   Lin, Cindy Shin Yi ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

acute inflammatory demyelinating polyneuropathy (AIDP); chronic inflammatory demyelinating polyneuropathy (CIDP); Guillain Barr syndrome; immunotherapy; nerve excitability

Indexed keywords

ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ACUTE ONSET CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPOLARIZING THRESHOLD ELECTROTONUS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; EARLY DIAGNOSIS; ELECTRICAL POTENTIAL PARAMETERS; FEMALE; FOLLOW UP; HUGHES FUNCTIONAL GRADING SCALE; HUMAN; HYPERPOLARIZING THRESHOLD ELECTROTONUS; LATENT PERIOD; MALE; MEDIAN NERVE; MEDICAL RESEARCH COUNCIL SUM SCORE; MIDDLE AGED; MUSCLE ACTION POTENTIAL; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NERVE CONDUCTION; NERVE EXCITABILITY; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTORY PERIOD; STAGING; STIMULUS RESPONSE; SUPEREXCITABILITY; YOUNG ADULT;

ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY (AIDP); CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP); GUILLAIN-BARRÉ SYNDROME; IMMUNOTHERAPY; NERVE EXCITABILITY;

ADOLESCENT; ADULT; AGED; EARLY DIAGNOSIS; ELECTROPHYSIOLOGICAL PROCESSES; FEMALE; FOLLOW-UP STUDIES; GUILLAIN-BARRE SYNDROME; HUMANS; MALE; MIDDLE AGED; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84905013775     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu158     Document Type: Article

References (32)

1. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990; 27: S21-4.
2. Berciano J, GarcýÁ A, Figols J, Muñoz R, Berciano MT, Lafarga M. Perineurium contributes to axonal damage in acute inflammatory demyelinating polyneuropathy. Neurology 2000; 55: 552-9.
3. Cappelen-Smith C, Kuwabara S, Lin CS, Mogyoros I, Burke D. Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2000; 48: 826-32.
4. Chiu SY, Ritchie JM. Evidence for the presence of potassium channels in the paranodal region of acutely demyelinated mammalian single nerve fibres. J Physiol 1981; 313: 415-37.
5. Comi C, Osio M, Ferretti M, Mesturini R, Cappellano G, Chiocchetti A, et al. Defective Fas-mediated T-cell apoptosis predicts acute onset CIDP. J Peripher Nerv Syst 2009; 14: 101-6.
6. Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillian-Barre syndrome. J Peripher Nerv Syst 2012; 17: 62-71.
7. Dionne A, Nicolle MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 2010; 41: 202-7.
8. Foster RE, Whalen CC, Waxman SG. Reorganization of the axonal membrane of demyelinated nerve fibers: Morphological evidence. Science 1980; 210: 661-3.
9. Han SE, Boland RA, Krishnan AV, Vucic S, Lin CS, Kiernan MC. Ischaemic sensitivity of axons in carpal tunnel syndrome. J Peripher Nerv Syst 2009; 14: 190-200.
10. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain-Barrésyndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995; 118 (Pt 3): 597-605.
11. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978; 2: 750-3.
12. Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000; 123 (Pt 12): 2542-51.
13. Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: A new approach in clinical testing. Muscle Nerve 2000; 23: 399-409.
14. Kleyweg RP, van Der MechéFG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain- Barrésyndrome. Muscle Nerve 1991; 14: 1103-9.
15. Kuwabara S, Ogawara K, Sung JY, Mori M, Kanai K, Hattori T, et al. Differences in membrane properties of axonal and demyelinating Guillain-Barrésyndromes. Ann Neurol 2002; 52: 180-7.
16. Lin CS, Krishnan AV, Park SB, Kiernan MC. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2011; 68: 862-9.
17. Lin CS, Kuwabara S, Cappelen-Smith C, Burke D. Responses of human sensory and motor axons to the release of ischaemia and to hyperpolarizing currents. J Physiol 2002; 541 (Pt 3): 1025-39.
18. McCombe PA, Pollard JC, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987; 111 (Pt 6): 1617-30.
19. Moldovan M, Krarup C. Mechanisms of hyperpolarization in regenerated mature motor axons in cat. J Physiol 2004; 560 (Pt 3): 807-19.
20. Odaka M, Yuki N, Hirata K. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain- Barrésyndrome. J Neurol 2003; 250: 913-6.
21. Panda S, Tripathi M. Anti-GQ1b IgG antibody syndrome: Clinical and immunological range. J Neurol Neurosurg Psychiatr 2002; 72: 418-9.
22. Pollard JD, Armati PJ. CIDP- The relevance of recent advances in Schwann cell/axonal neurobiology. J Peripher Nerv Syst 2011; 16: 15-23.
23. Powell HC, Myers RR, Mizisin AP, Olee T, Brotoff SW. Response of the axon and barrier endothelium to experimental allergic neuritis induced by autoreactive T cell lines. Acta Neuropathol 1991; 82: 364-77.
24. Ritchie JM, Rogart RB. Density of sodium channels in mammalian myelinated nerve fibers and nature of the axonal membrane under the myelin sheath. Proc Natl Acad Sci USA 1977; 74: 211-5.
25. Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barrésyndrome: A prospective study. Neurology 2010; 74: 1680-6.
26. Stephanova DI, Daskalova M. Differences in potentials and excitability properties in simulated cases of demyelinating neuropathies. Part III. Paranodal internodal demyelination. Clin Neurophys 2005a; 116: 2334-41.
27. Stephanova DI, Daskalova M. Differences in potentials and excitability properties in simulated cases of demyelinating neuropathies. Part II. Paranodal demyelination. Clin Neurophys 2005b; 116: 1159-66.
28. Sung JY, Kuwabara S, Kaji R, Ogawara K, Mori M, Kanai K, et al. Threshold electrotonus in chronic inflammatory demyelinating polyneuropathy: Correlation with clinical profiles. Muscle Nerve 2004; 29: 28-37.
29. Van Den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al. Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 2010; 17: 356-63.
30. Van Der MechéFG, Van Doorn PA, Meulstee J, Jennekens FC. GBSconsensus group of the Dutch Neuromuscular Research Support Centre. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 2001; 45: 133-9.
31. Van Doorn PA. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). Presse Med 2013; 42 (Pt 2): E193-201.
32. Yuki N, Hartung HP. Guillain-Barrésyndrome. N Engl J Med 2012; 366: 2294-304.